Class 4 Medicines Defect Notification: Lexon UK Ltd, Moclobemide 150mg tablets, EL(25)A/50
Source: gov.uk (2025-11-25)

Lexon UK Ltd has informed the MHRA that the Patient Information Leaflet  (PIL) in the cartons for the batches listed in this notification is missing important updated safety information.

DMRC reference number

DMRC - 37693641

Marketing Authorisation Holder

Lexon UK Ltd

Medicine Details

Moclobemide 150mg tablets

PLPI: 15184/1476

Active ingredient: Moclobemide

SNOMED code: 42274911000001106

GTIN: xx-xxxx-xxxx

Affected Lot Batch Numbers

Background

Lexon UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the cartons for the batches listed in this notification is missing important updated safety information.

Lexon UK Ltd has confirmed that 326 packs of the affected batches are already distributed in the market. The missing information from the PIL is detailed in this notification:

2. What you need to know before you take Moclobemide

In the section, “Take special care with Moclobemide”, “Check with your doctor or pharmacist before taking Moclobemide if:”

You require pain relief with buprenorphine. The use of buprenorphine together with Moclobemide can lead to serotonin syndrome, a potentially life-threatening condition (see “Possible side effects”).

The addition of Buprenorphine in the section “Do not take Moclobemide, and tell your doctor or pharmacist if you are taking the following”

4. Under Rare side effects (affects 1 in 10,000 people)

Serotonin syndrome, you may experience symptoms such as involuntary, rhythmic contraction of muscles, including the muscles that control movement of the eye, agitation, hallucinations, coma, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension, body temperature of above 38°C, irregular heartbeat, losing consciousness or having fits (seizures). Contact your doctor when experiencing such symptoms.

Advice for Healthcare Professionals:

There is no risk to product quality or impact to safety of the medicines listed in this notification because of this missing information. Healthcare professionals are advised to review the information contained within this notification and take this into account when dispensing this product, especially for new patients.

If the medicine listed in this notification are dispensed, ensure that patients are aware of the missing information. Please see updated PIL (https://mhraproducts4853.blob.core.windows.net/docs/f2f02e1df9a164920b44a0662f1619731becd2a3) for the correct information.

Upon request, Lexon UK Ltd will provide hard copies of the updated PIL to pharmacies so that any remaining stock in the dispensary can be supplemented with the correct PIL information. To request hard copies of the PIL, please contact Lexon UK Ltd with your details, i.e. address, product with batch details, required number of leaflets.

Advice for Patients:

Patients should be aware that packs of Moclobemide 150mg Tablets, Batches I3602 and H4610, contain the incorrect Patient Information Leaflet (PIL). The missing safety information is listed in this notification and if you have any additional concerns relating to this information, please contact your pharmacist or prescriber.

The missing information, summarised in this notification, does not change or affect the quality of the product. Patients can continue to safely take this medicine unless they have concerns related to the missing information.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme (https://yellowcard.mhra.gov.uk/).

Additional information:

For all medical information enquiries and information on this product, please email xxx@xxx.xx (mailto:xxx@xxx.xx), or telephone xx-xxxx-xxxx. For stock control enquiries please email xxx@xxx.xx (mailto:xxx@xxx.xx), or telephone xx-xxxx-xxxx.

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre10 South ColonnadeCanary WharfLondonE14 4PU

Telephone xx-xxxx-xxxx

xxx@xxx.xx (mailto:xxx@xxx.xx)

Download document

Class 4 Medicines Defect Notification: Lexon UK Ltd, Moclobemide 150mg tablets, EL(25)A/50 (https://assets.publishing.service.gov.uk/media/692590be9fd433badebc3135/Class_4_Medicines_Defect_Notification_Lexon_UK_Ltd__Moclobemide_150mg_tablets__EL_25_A50.pdf)